Detailed explanation of the latest selling price and purchasing channels of Assimini in 2024

Aximini, this innovative drug known as the third generation tyrosine kinase inhibitor (TKI), is gradually becoming the new favorite in the treatment of chronic myelogenous leukemia (CML). Its unique feature is that it can accurately inhibit the abnormal protein activity caused by BCR-ABL1 gene mutation, thereby effectively blocking the crazy proliferation of cancer cells. Compared with traditional TKI drugs, aceminib has a more advanced mechanism of action. It targets ABL1kinasemyristoyl The pan>binding pocket makes it impossible for mutations that confer resistance to first- and second-generation TKIs, especially the difficult-to-break T315I mutation.

Aximini's clinical performance is eye-catching, especially in patients who have experienced multiple TKI treatments but still have no effect. The side effects are relatively mild and are generally tolerated by patients. Common symptoms such as fatigue, nausea, headache, etc. will not have much impact on patients' daily life.

However, for patients, the price of drugs is always an unavoidable issue. Unfortunately, Aceminib is not currently available in China, and patients cannot purchase it directly in domestic pharmacies. However, patients can still obtain the drug through overseas channels. Abroad, Acemini has two options: original drugs and generic drugs. Original drugs mainly come from Europe and are expensive, with a box often costing tens of thousands of yuan, which is undoubtedly a heavy financial burden for many patients. Generic drugs are mainly from Laos and are relatively affordable, with a box costing only more than 4,000 yuan. Despite the huge price disparity, generic drugs in Laos are quite reliable with the original drugs in terms of drug ingredients and therapeutic effects, making them the first choice for many patients.

To sum up, Asiminib has opened up a new treatment path for CML patients, especially for those patients who have been repeatedly frustrated in previous generations of TKI drug treatments. It has brought unprecedented hope.